Several other research analysts also recently commented on EIGR. Zacks Investment Research raised Eiger Biopharmaceuticals from a hold rating to a buy rating and set a $16.00 price objective on the stock in a research note on Monday, January 13th. LADENBURG THALM/SH SH boosted their price objective on Eiger Biopharmaceuticals from $28.00 to $31.00 and gave the company a buy rating in a research note on Wednesday, January 22nd. Wedbush reissued a buy rating and issued a $35.00 target price on shares of Eiger Biopharmaceuticals in a report on Monday, January 6th. Gilford Securities initiated coverage on shares of Eiger Biopharmaceuticals in a report on Monday, December 16th. They issued an average rating for the company. Finally, BidaskClub upgraded shares of Eiger Biopharmaceuticals from a sell rating to a hold rating in a research note on Thursday, November 28th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and an average target price of $26.79.
Shares of Eiger Biopharmaceuticals stock opened at $12.91 on Friday. Eiger Biopharmaceuticals has a one year low of $9.38 and a one year high of $15.82. The stock’s fifty day moving average is $13.97 and its 200 day moving average is $11.76. The stock has a market cap of $318.50 million, a P/E ratio of -3.88 and a beta of 1.20. The company has a debt-to-equity ratio of 0.44, a quick ratio of 6.83 and a current ratio of 6.83.
In other news, Director Thomas John Dietz purchased 4,000 shares of the stock in a transaction on Friday, January 10th. The shares were acquired at an average price of $13.84 per share, with a total value of $55,360.00. Following the completion of the acquisition, the director now directly owns 24,000 shares of the company’s stock, valued at $332,160. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 5.80% of the stock is owned by insiders.
Large investors have recently modified their holdings of the business. Psagot Investment House Ltd. purchased a new position in Eiger Biopharmaceuticals during the third quarter valued at approximately $26,000. Bank of Montreal Can purchased a new position in Eiger Biopharmaceuticals during the second quarter valued at approximately $28,000. Lindbrook Capital LLC purchased a new position in Eiger Biopharmaceuticals during the third quarter valued at approximately $36,000. Tower Research Capital LLC TRC lifted its holdings in Eiger Biopharmaceuticals by 1,719.7% during the second quarter. Tower Research Capital LLC TRC now owns 4,895 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 4,626 shares in the last quarter. Finally, Metropolitan Life Insurance Co NY purchased a new position in Eiger Biopharmaceuticals during the third quarter valued at approximately $94,000. 83.68% of the stock is currently owned by institutional investors and hedge funds.
Eiger Biopharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.
Recommended Story: How to interpret the current ratio
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.